Long-term efficacy and safety of rituximab in igg4-related disease: data from a french nationwide study of thirty-three patients

HIGHLIGHTS

• who: Mikael Ebbo and colleagues from the of Internal Medicine and Clinical Immunology, Dijon University Hospital, Dijon, France have published the article: Long-term efficacy and safety of rituximab in IgG4-related disease: Data from a French nationwide study of thirty-three patients, in the Journal: PLOS ONE | https://doi.org/10.1371/journal.pone [0183844]. September 15, 2017 of September/15,/2017
• what: The authors report on the use of RTX in patients with IgG4-RD enrolled in a nationwide French multicenter cohort. This study shows that systematic maintenance retreatment with RTX was associated . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or Email

  Password

  Remember me

  Lost your password?

  If you don't have an account, you can create one here.